Audentes Therapeutics (BOLD) Reports Dosing of First Patient in ASPIRO, the Phase 1/2 Clinical Trial of AT132
Tweet Send to a Friend
Audentes Therapeutics, Inc. (NASDAQ: BOLD) today announced it has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
